Drugs / Rutan
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05862883 | Jun 2021 → Jul 2022 | COVID-19 | Research Institute of Virology, Ministry of Health of the Republic of Uzbekistan | Completed | No outcome recorded |
| Phase 2 | NCT05859919 | Oct 2020 → Sep 2021 | — | Research Institute of Virology, Ministry of Health of the Republic of Uzbekistan | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rutan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05862883 ↗ |
| Route | Oral | “Rutan 25 mg oral drug tablets” PMID 38093975 ↗ Nov 2023 |